Neary D, Snowden J, Mann D (2005) Frontotemporal dementia. Lancet Neurol 4(11):771–780
Article
PubMed
Google Scholar
Irwin DJ, Trojanowski JQ, Grossman M (2013) Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer’s disease. Front Aging Neurosci 5:6
Article
CAS
PubMed
PubMed Central
Google Scholar
Sieben A, Van Langenhove T, Engelborghs S, Martin J-J, Boon P, Cras P et al (2012) The genetics and neuropathology of frontotemporal lobar degeneration. Acta Neuropathol 124(3):353–372. https://doi.org/10.1007/s00401-012-1029-x
Article
CAS
PubMed
PubMed Central
Google Scholar
Josephs KA, Hodges JR, Snowden JS, MacKenzie IR, Neumann M, Mann DM et al (2011) Neuropathological background of phenotypical variability in frontotemporal dementia. Acta Neuropathol 122:137–153
Article
PubMed
PubMed Central
Google Scholar
Seelaar H, Kamphorst W, Rosso SM, Azmani A, Masdjedi R, De Koning I et al (2008) Distinct genetic forms of frontotemporal dementia. Neurology 71:1220–1226
Article
CAS
PubMed
Google Scholar
Warren JD, Rohrer JD, Rossor MN (2013) Frontotemporal dementia. BMJ 347(3):f4827–f4827. https://doi.org/10.1136/bmj.f4827
Article
PubMed
PubMed Central
Google Scholar
Rabinovici GD, Miller BL (2010) Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management. CNS Drugs 24(5):375–398
Article
CAS
PubMed
PubMed Central
Google Scholar
Pose M, Cetkovich M, Gleichgerrcht E, Ibáñez A, Torralva T, Manes F (2013) The overlap of symptomatic dimensions between frontotemporal dementia and several psychiatric disorders that appear in late adulthood. Int Rev Psychiatry 25:159–167
Article
PubMed
Google Scholar
Zetterberg H, van Swieten JC, Boxer AL, Rohrer JD (2019) Review: Fluid biomarkers for frontotemporal dementias. Neuropathol Appl Neurobiol 45(1):81–87
Article
CAS
PubMed
Google Scholar
Meeter LH, Kaat LD, Rohrer JD, Van Swieten JC (2017) Imaging and fluid biomarkers in frontotemporal dementia. Nat Rev Neurol 13:406–419
Article
CAS
PubMed
Google Scholar
Meeter LHH, Vijverberg EG, Del Campo M, Rozemuller AJM, Donker Kaat L, de Jong FJ et al (2018) Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum. Neurology 90(14):e1231–e1239
Article
CAS
PubMed
PubMed Central
Google Scholar
Pijnenburg YAL, Verwey NA, van der Flier WM, Scheltens P, Teunissen CE (2015) Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes. Alzheimer’s dement diagnosis. Assess Dis Monit 1:505–512
Google Scholar
Gold L, Ayers D, Bertino J, Bock C, Bock A, Brody EN et al (2010) Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS ONE 5(12):e15004
Article
CAS
PubMed
PubMed Central
Google Scholar
Keefe AD, Pai S, Ellington A (2010) Aptamers as therapeutics. Nat Rev Drug Discov 9(7):537–550
Article
CAS
PubMed
PubMed Central
Google Scholar
Davies DR, Gelinas AD, Zhang C, Rohloff JC, Carter JD, O’Connell D et al (2012) Unique motifs and hydrophobic interactions shape the binding of modified DNA ligands to protein targets. Proc Natl Acad Sci USA 109(49):19971–19976
Article
CAS
PubMed
PubMed Central
Google Scholar
Sattlecker M, Kiddle SJ, Newhouse S, Proitsi P, Nelson S, Williams S et al (2014) Alzheimer’s disease biomarker discovery using SOMAscan multiplexed protein technology. Alzheimer’s Dement 10:724–734
Article
Google Scholar
Shi L, Westwood S, Baird AL, Winchester L, Dobricic V, Kilpert F et al (2019) Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. Alzheimer’s Dement 15(11):1478–1488
Article
Google Scholar
Westwood S, Baird AL, Hye A, Ashton NJ, Nevado-Holgado AJ, Anand SN et al (2018) Plasma protein biomarkers for the prediction of CSF amyloid and tau and [18F]-flutemetamol PET scan result. Front Aging Neurosci 10:409
Article
CAS
PubMed
PubMed Central
Google Scholar
Rosso SM, Kaat LD, Baks T, Joosse M, De Koning I, Pijnenburg Y et al (2003) Frontotemporal dementia in The Netherlands: patient characteristics and prevalence estimates from a population-based study. Brain 126:2016–2022
Article
PubMed
Google Scholar
van der Flier WM, Scheltens P (2018) Amsterdam dementia cohort: performing research to optimize care. Perry G, Avila J, Tabaton M, Zhu X, editors. J Alzheimer’s Dis 62(3):1091–1111. https://doi.org/10.3233/JAD-170850
Article
Google Scholar
Van Der Flier WM, Pijnenburg YAL, Prins N, Lemstra AW, Bouwman FH, Teunissen CE et al (2014) Optimizing patient care and research: the Amsterdam dementia cohort. J Alzheimer’s Dis 41(1):313–327
Article
Google Scholar
Aalten P, Ramakers IHGB, Biessels GJ, de Deyn PP, Koek HL, OldeRikkert MGM et al (2014) The Dutch Parelsnoer Institute—neurodegenerative diseases; methods, design and baseline results. BMC Neurol 14:1–8
Article
Google Scholar
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34(7):939–939. https://doi.org/10.1212/WNL.34.7.939
Article
CAS
PubMed
Google Scholar
Verberk IMW, Misdorp EO, Koelewijn J, Ball AJ, Blennow K, Dage JL et al (2021) Characterization of pre-analytical sample handling effects on a panel of Alzheimer’s disease–related blood-based biomarkers: results from the standardization of Alzheimer’s blood biomarkers (SABB) working group. Alzheimer’s Dement. https://doi.org/10.1002/alz.12510
Article
Google Scholar
Del Campo M, Hoozemans JJM, Dekkers L-L, Rozemuller AJ, Korth C, Müller-Schiffmann A et al (2014) BRI2-BRICHOS is increased in human amyloid plaques in early stages of Alzheimer’s disease. Neurobiol Aging 35(7):1596–1604
Article
PubMed
Google Scholar
Mackenzie IRA, Neumann M, Baborie A, Sampathu DM, Du Plessis D, Jaros E et al (2011) A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol 122:111–113
Article
PubMed
PubMed Central
Google Scholar
Lee EB, Porta S, Michael Baer G, Xu Y, Suh ER, Kwong LK et al (2017) Expansion of the classification of FTLD-TDP: distinct pathology associated with rapidly progressive frontotemporal degeneration. Acta Neuropathol 134:65–78
Article
CAS
PubMed
PubMed Central
Google Scholar
Cairns NJ, Bigio EH, Mackenzie IRA, Neumann M, Lee VMY, Hatanpaa KJ et al (2007) Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the consortium for frontotemporal lobar degeneration. Acta Neuropathol 114:5–22
Article
PubMed
PubMed Central
Google Scholar
Goeman JJ, Van de Geer S, De Kort F, van Houwellingen HC (2004) A global test for groups of genes: testing association with a clinical outcome. Bioinformatics 20:93–99
Article
CAS
PubMed
Google Scholar
Ashton NJ, Hye A, Rajkumar AP, Leuzy A, Snowden S, Suárez-Calvet M et al (2020) An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. Nat Rev Neurol 16:265–284
Article
PubMed
Google Scholar
Teunissen CE, Elias N, Koel-Simmelink MJA, Durieux-Lu S, Malekzadeh A, Pham TV et al (2016) Novel diagnostic cerebrospinal fluid biomarkers for pathologic subtypes of frontotemporal dementia identified by proteomics. Alzheimer’s dement diagnosis. Assess Dis Monit 2:86–94
Google Scholar
van der Ende EL, Meeter LH, Stingl C, van Rooij JGJ, Stoop MP, Nijholt DAT et al (2019) Novel CSF biomarkers in genetic frontotemporal dementia identified by proteomics. Ann Clin Transl Neurol 6(4):698–707. https://doi.org/10.1002/acn3.745
Article
CAS
PubMed
PubMed Central
Google Scholar
Dayon L, Cominetti O, Wojcik J, Galindo AN, Oikonomidi A, Henry H et al (2019) Proteomes of paired human cerebrospinal fluid and plasma: relation to blood-brain barrier permeability in older adults. J Proteome Res 18(3):1162–1174. https://doi.org/10.1021/acs.jproteome.8b00809
Article
CAS
PubMed
Google Scholar
Whelan CD, Mattsson N, Nagle MW, Vijayaraghavan S, Hyde C, Janelidze S et al (2019) Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer’s disease. Acta Neuropathol Commun 7(1):169. https://doi.org/10.1186/s40478-019-0795-2
Article
CAS
PubMed
PubMed Central
Google Scholar
del Campo M, Zetterberg H, Gandy S, Onyike CU, Oliveira F, Udeh-Momoh C et al (2022) New developments of biofluid-based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia. Alzheimer’s Dement. https://doi.org/10.1002/alz.12643
Article
Google Scholar
Ouaissi MA, Capron A (1985) Fibronectins: structure and functions. Ann l’Inst Pasteur Immunol 136(2):169–185
Article
Google Scholar
Bader JM, Geyer PE, Müller JB, Strauss MT, Koch M, Leypoldt F et al (2020) Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer’s disease. Mol Syst Biol. https://doi.org/10.15252/msb.20199356
Article
PubMed
PubMed Central
Google Scholar
Lemańska-Perek A, Leszek J, Krzyanowska-Golab D, Radzik J, Katnik-Prastowska MI (2009) Molecular status of plasma fibronectin as an additional biomarker for assessment of Alzheimer’s dementia risk. Dement Geriatr Cogn Disord 28(4):338–342
Article
PubMed
Google Scholar
Lepelletier F-X, Mann DMA, Robinson AC, Pinteaux E, Boutin H (2017) Early changes in extracellular matrix in Alzheimer’s disease. Neuropathol Appl Neurobiol 43(2):167–182
Article
CAS
PubMed
Google Scholar
Noda Y, Kuzuya A, Tanigawa K, Araki M, Kawai R, Ma B et al (2018) Fibronectin type III domain-containing protein 5 interacts with APP and decreases amyloid β production in Alzheimer’s disease. Mol Brain 11(1):61. https://doi.org/10.1186/s13041-018-0401-8
Article
CAS
PubMed
PubMed Central
Google Scholar
Westwood S, Leoni E, Hye A, Lynham S, Khondoker MR, Ashton NJ et al (2016) Blood-based biomarker candidates of cerebral amyloid using PiB PET in non-demented elderly. J Alzheimers Dis 52(2):561–572
Article
CAS
PubMed
PubMed Central
Google Scholar
Thambisetty M, Simmons A, Hye A, Campbell J, Westman E, Zhang Y et al (2011) Plasma biomarkers of brain atrophy in Alzheimer’s disease. PLoS ONE 6:e28527
Article
CAS
PubMed
PubMed Central
Google Scholar
Shi L, Buckley NJ, Bos I, Engelborghs S, Sleegers K, Frisoni GB et al (2021) Plasma proteomic biomarkers relating to Alzheimer’s disease: a meta-analysis based on our own studies. Front Aging Neurosci. https://doi.org/10.3389/fnagi.2021.712545/full
Article
PubMed
PubMed Central
Google Scholar
Cortes-Canteli M, Zamolodchikov D, Ahn HJ, Strickland S, Norris EH (2012) Fibrinogen and altered hemostasis in Alzheimer’s disease. de la Torre J, editor. J Alzheimer’s Dis 32(3):599–608. https://doi.org/10.3233/JAD-2012-120820
Article
CAS
Google Scholar
Moumen A, Masterson P, O’Connor MJ, Jackson SP (2005) hnRNP K: an HDM2 target and transcriptional coactivator of p53 in response to DNA damage. Cell 123(6):1065–1078
Article
CAS
PubMed
Google Scholar
Zhang Q, Ma C, Gearing M, Wang PG, Chin L-S, Li L (2018) Integrated proteomics and network analysis identifies protein hubs and network alterations in Alzheimer’s disease. Acta Neuropathol Commun 6(1):19
Article
PubMed
PubMed Central
Google Scholar
Bampton A, Gatt A, Humphrey J, Cappelli S, Bhattacharya D, Foti S et al (2021) HnRNP K mislocalisation is a novel protein pathology of frontotemporal lobar degeneration and ageing and leads to cryptic splicing. Acta Neuropathol 142:609–627
Article
CAS
PubMed
PubMed Central
Google Scholar
Moujalled D, Grubman A, Acevedo K, Yang S, Ke YD, Moujalled DM et al (2017) TDP-43 mutations causing amyotrophic lateral sclerosis are associated with altered expression of RNA-binding protein hnRNP K and affect the Nrf2 antioxidant pathway. Hum Mol Genet 26:1732–1746
Article
CAS
PubMed
Google Scholar
Peyvandi F, Garagiola I, Baronciani L (2011) Role of von Willebrand factor in the haemostasis. Blood Transf 9:s3
Google Scholar
Yavuz BB, Dede DS, Yavuz B, Cankurtaran M, Halil M, Ulger Z et al (2010) Potential biomarkers for vascular damage in ALzheimer’s disease: thrombomodulin and von Willebrand factor. J Nutr Health Aging 14(6):439–441. https://doi.org/10.1007/s12603-010-0043-8
Article
CAS
PubMed
Google Scholar
Thomas T, Miners S, Love S (2015) Post-mortem assessment of hypoperfusion of cerebral cortex in Alzheimer’s disease and vascular dementia. Brain 138:1059–1069
Article
PubMed
Google Scholar
Wolters FJ, Boender J, De Vries PS, Sonneveld MA, Koudstaal PJ, De Maat MP et al (2018) Von Willebrand factor and ADAMTS13 activity in relation to risk of dementia: a population-based study. Sci Rep 8(1):1–10
Article
Google Scholar
Mielke MM, Aakre JA, Algeciras-Schimnich A, Proctor NK, Machulda MM, Eichenlaub U et al (2021) Comparison of CSF phosphorylated tau 181 and 217 for cognitive decline. Alzheimer’s Dement. https://doi.org/10.1002/alz.12415
Article
Google Scholar
Thijssen EH, La Joie R, Wolf A, Strom A, Wang P, Iaccarino L et al (2020) Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration. Nat Med 26:387–397
Article
CAS
PubMed
PubMed Central
Google Scholar
Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE et al (2020) Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia. Nat Med 26:379–386
Article
CAS
PubMed
Google Scholar
Hu WT, Chen-Plotkin A, Grossman M, Arnold SE, Clark CM, Shaw LM et al (2010) Novel CSF biomarkers for frontotemporal lobar degenerations. Neurology 75(23):2079–2086. https://doi.org/10.1212/WNL.0b013e318200d78d
Article
CAS
PubMed
PubMed Central
Google Scholar
Mackenzie IRA, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kril J et al (2010) Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol 119(1):1–4
Article
PubMed
Google Scholar
Buée L, Bussière T, Buée-Scherrer V, Delacourte A, Hof PR (2000) Tau protein isoforms, phosphorylation and role in neurodegenerative disorders11These authors contributed equally to this work. Brain Res Rev 33(1):95–130
Article
PubMed
Google Scholar
Davies P, Resnick J, Resnick B, Gilman S, Growdon JH, Khachaturian ZS et al (1998) Consensus report of the Working Group on: “molecular and biochemical markers of Alzheimer’s disease”. The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and the National Institute on Aging Working Group. Neurobiol Aging 19(2):109–116
Article
Google Scholar
Umoh ME, Dammer EB, Dai J, Duong DM, Lah JJ, Levey AI et al (2018) A proteomic network approach across the ALS-FTD disease spectrum resolves clinical phenotypes and genetic vulnerability in human brain. EMBO Mol Med 10(1):48–62
Article
CAS
PubMed
Google Scholar
Chen M, Xia W (2020) Proteomic profiling of plasma and brain tissue from Alzheimer’s disease patients reveals candidate network of plasma biomarkers. J Alzheimers Dis 76(1):349–368
Article
CAS
PubMed
PubMed Central
Google Scholar
Wang H, Dey KK, Chen PC, Li Y, Niu M, Cho JH et al (2020) Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer’s disease. Mol Neurodegener 15:1–20
Article
Google Scholar
Moscoso A, Grothe MJ, Ashton NJ, Karikari TK, Lantero Rodríguez J, Snellman A et al (2021) Longitudinal associations of blood phosphorylated Tau181 and neurofilament light chain with neurodegeneration in Alzheimer disease. JAMA Neurol 78(4):396–406
Article
PubMed
Google Scholar
SomaLogic Inc. SOMAscan technical note
Suhre K, McCarthy MI, Schwenk JM (2021) Genetics meets proteomics: perspectives for large population-based studies. Nat Rev Genet 22:19–37
Article
CAS
PubMed
Google Scholar
Ducharme S, Dols A, Laforce R, Devenney E, Kumfor F, van den Stock J et al (2020) Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders. Brain 143(6):1632–1650
Article
PubMed
PubMed Central
Google Scholar
Willemse EAJ, Scheltens P, Teunissen CE, Vijverberg EGB (2021) A neurologist’s perspective on serum neurofilament light in the memory clinic: a prospective implementation study. Alzheimer’s Res Ther 13:1–11
Google Scholar
Katisko K, Cajanus A, Jääskeläinen O, Kontkanen A, Hartikainen P, Korhonen VE et al (2020) Serum neurofilament light chain is a discriminative biomarker between frontotemporal lobar degeneration and primary psychiatric disorders. J Neurol 267(1):162–167
Article
CAS
PubMed
Google Scholar
Rayaprolu S, Higginbotham L, Bagchi P, Watson CM, Zhang T, Levey AI et al (2021) Systems-based proteomics to resolve the biology of Alzheimer’s disease beyond amyloid and tau. Neuropsychopharmacology 46(1):98–115
Article
CAS
PubMed
Google Scholar
Hampel H, Nisticò R, Seyfried NT, Levey AI, Modeste E, Lemercier P et al (2021) Omics sciences for systems biology in Alzheimer’s disease: state-of-the-art of the evidence. Ageing Res Rev 69:101346
Article
CAS
PubMed
Google Scholar